Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Pediatric r/r B-ALL
NCT05667506Phase 2Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Juventas Cell Therapy Ltd. Primary endpoint: Overall Remission Rate at 3 months. Started Feb 2023; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05667506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667506.